To create Avidocins, Pylum engineers the bacteriocin’s phage-like tendrils to target specific receptors on the surface of pathogenic strains of bacteria. The rest of the molecule remains unchanged.

Despite numerous therapeutic research efforts, treatment of BV remains cumbersome and clinicians are currently rather poorly armed to treat BV properly in the long run. Moreover, appraisal of the ...